The trial enrolled patients who received a triplet chemotherapy regimen of nab-paclitaxel, cisplatin, and gemcitabine.

Immutep Limited (NASDAQ:IMMP) shares plunged roughly 80% on Friday after the biotechnology company announced it would discontinue its Phase III TACTI-004 clinical trial following a futility review.

Daiichi Sankyo announced that the first patient has been dosed in the global phase 3 TROPION-Lung17 trial. The study is evaluating DATROWAY in patients with locally advanced or metastatic nonsquamous ...

Immutep Limited IMMP shares are tumbling on Friday following the company’s update for the TACTI-004 Phase 3 trial. The Australia-based biotech announced that the Independent Data Monitoring Committee ...

March is Colorectal Cancer Awareness Month. See how American Cancer Society researchers are helping put an end to this disease. American Cancer Society (ACS) researchers study the most effective ways ...

The future of cancer drug research just might be in Omaha, Nebraska, between a Panda Express and a Mattress Firm. A big draw is speed: Nordquist says he can open a trial in as little as two weeks, ...

In late January 2026, cancer research advocates won a major victory in Congress. Working with a bipartisan group of congressional leaders, they secured a $128 million increase in funding for the ...

Fred Hutch Cancer Center researchers are seeking better ways to prevent, detect and treat bladder cancer. We are also working to better understand the factors that affect each person’s risk for this ...

Cancer is caused by faulty genes, but what also shapes a cancer cell's behavior is how a gene's instructions are trimmed and ...

Martei is a medical oncologist, cancer outcomes researcher, and an assistant professor of medicine at the University of Pennsylvania. At the American Society of Clinical Oncology annual meeting last ...